FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310104977> ?p ?o ?g. }

• W4310104977 endingPage "7696" @default.
• W4310104977 startingPage "7695" @default.
• W4310104977 abstract "Introduction: For patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HCT) in first complete remission (CR1), measurable residual disease (MRD) prior to HCT is strongly associated with post-HCT relapse rates and overall survival (OS). However, for a growing number of patients with ALL, HCT is deferred until the second remission (CR2) or beyond. It is unclear whether pre-transplant MRD assessment is also prognostic in the setting of HCT beyond CR1. Methods: We performed a single center retrospective study to test the hypothesis that pre-transplant MRD positivity is associated with outcomes in patients receiving HCT in CR2 or beyond for ALL. MRD was measured by 6-color flow cytometry with a sensitivity of 0.01%. Consecutive pediatric and adult patients who underwent first allogeneic HCT between the years 2004-2021 for ALL in CR2 or beyond were included. Results: We identified 162 patients (Table 1), 123 (76%) with B-ALL and the remainder with T-ALL. The majority (80%, n=129) of patients were in CR2 at the time of HCT, the remainder in third CR or beyond (CR3+). One hundred and five (65%) patients were male and median age at transplant was 31 (range 4-69) years. Graft source was either matched unrelated donor (MUD) (43%, n=69), matched sibling donor (MSD) (24%, n=39), haploidentical (18%, n=29) or cord blood transplantation (CBT) (15%, n=25). Pre-HCT MRD status was determined for 150 (93%) of patients and of those was positive in 43 (26%). Subsequent analyses were limited to the subset of patients with known MRD status. There was no statistical difference in characteristics according to MRD status except for higher proportion of CR3+ patients (33% vs. 16%, p=0.02) and comorbidity index >2 (70% vs. 40%, p=0.001) in MRD positive vs. negative patients. The median follow-up in surviving patients was 62 (range 20-104) and 47 (range: 2-171) months in MRD positive and negative patients, respectively. In multivariate analysis (MVA) evaluating transplantation outcomes at 3 years, pre-HCT MRD positivity was associated with a higher rate of disease relapse (HR 1.9, 95% CI 1.1-3.6; p=0.02); but it had no impact on non-relapse mortality (NRM) (HR 0.8, 95% CI 0.4-1.8; p=0.6). Subset analyses showed that these trends were consistent for patients receiving HCT in CR2 or CR3+; however the impact on disease relapse was more pronounced for patients in CR2 at HCT. MRD positivity was also associated with less favorable overall (HR 1.96, 95% CI 1.2-3.3; p=0.01) and progression-free survival (PFS) (HR 2.5, 95% CI 1.5-4.2; p<0.001) for patients receiving HCT in CR2. MRD was not associated with OS (HR 0.9, 95% CI 0.4-2, p=0.8) or PFS (HR 0.8, 95% CI 0.3-1.7, p=0.5) for patients receiving HCT in CR3+. As shown in Figure 1 A-B, OS and PFS were significantly superior for MRD negative patients receiving HCT in CR2. OS and PFS for MRD positive patients in CR2 were comparable to patients receiving HCT in CR3+. Conclusions: Pre-transplant MRD positivity is predictive of disease relapse in patients undergoing HCT for ALL in CR2 or beyond; however, the survival advantage associated with MRD negativity maybe limited to patients undergoing HCT in CR2. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310104977 created "2022-11-30" @default.
• W4310104977 creator A5000750846 @default.
• W4310104977 creator A5015342719 @default.
• W4310104977 creator A5034104852 @default.
• W4310104977 creator A5039986529 @default.
• W4310104977 creator A5047522685 @default.
• W4310104977 creator A5048913229 @default.
• W4310104977 creator A5050962913 @default.
• W4310104977 creator A5055885795 @default.
• W4310104977 creator A5066894053 @default.
• W4310104977 creator A5067252491 @default.
• W4310104977 creator A5068834306 @default.
• W4310104977 creator A5069460930 @default.
• W4310104977 creator A5071516639 @default.
• W4310104977 creator A5085076031 @default.
• W4310104977 creator A5091492845 @default.
• W4310104977 date "2022-11-15" @default.
• W4310104977 modified "2023-09-27" @default.
• W4310104977 title "Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond" @default.
• W4310104977 doi "https://doi.org/10.1182/blood-2022-155916" @default.
• W4310104977 hasPublicationYear "2022" @default.
• W4310104977 type Work @default.
• W4310104977 citedByCount "0" @default.
• W4310104977 crossrefType "journal-article" @default.
• W4310104977 hasAuthorship W4310104977A5000750846 @default.
• W4310104977 hasAuthorship W4310104977A5015342719 @default.
• W4310104977 hasAuthorship W4310104977A5034104852 @default.
• W4310104977 hasAuthorship W4310104977A5039986529 @default.
• W4310104977 hasAuthorship W4310104977A5047522685 @default.
• W4310104977 hasAuthorship W4310104977A5048913229 @default.
• W4310104977 hasAuthorship W4310104977A5050962913 @default.
• W4310104977 hasAuthorship W4310104977A5055885795 @default.
• W4310104977 hasAuthorship W4310104977A5066894053 @default.
• W4310104977 hasAuthorship W4310104977A5067252491 @default.
• W4310104977 hasAuthorship W4310104977A5068834306 @default.
• W4310104977 hasAuthorship W4310104977A5069460930 @default.
• W4310104977 hasAuthorship W4310104977A5071516639 @default.
• W4310104977 hasAuthorship W4310104977A5085076031 @default.
• W4310104977 hasAuthorship W4310104977A5091492845 @default.
• W4310104977 hasBestOaLocation W43101049771 @default.
• W4310104977 hasConcept C126322002 @default.
• W4310104977 hasConcept C143998085 @default.
• W4310104977 hasConcept C2776694085 @default.
• W4310104977 hasConcept C2777408962 @default.
• W4310104977 hasConcept C2778461978 @default.
• W4310104977 hasConcept C2779823535 @default.
• W4310104977 hasConcept C2779972918 @default.
• W4310104977 hasConcept C2781107101 @default.
• W4310104977 hasConcept C28328180 @default.
• W4310104977 hasConcept C2909962599 @default.
• W4310104977 hasConcept C2911091166 @default.
• W4310104977 hasConcept C3018657049 @default.
• W4310104977 hasConcept C54355233 @default.
• W4310104977 hasConcept C71924100 @default.
• W4310104977 hasConcept C86803240 @default.
• W4310104977 hasConceptScore W4310104977C126322002 @default.
• W4310104977 hasConceptScore W4310104977C143998085 @default.
• W4310104977 hasConceptScore W4310104977C2776694085 @default.
• W4310104977 hasConceptScore W4310104977C2777408962 @default.
• W4310104977 hasConceptScore W4310104977C2778461978 @default.
• W4310104977 hasConceptScore W4310104977C2779823535 @default.
• W4310104977 hasConceptScore W4310104977C2779972918 @default.
• W4310104977 hasConceptScore W4310104977C2781107101 @default.
• W4310104977 hasConceptScore W4310104977C28328180 @default.
• W4310104977 hasConceptScore W4310104977C2909962599 @default.
• W4310104977 hasConceptScore W4310104977C2911091166 @default.
• W4310104977 hasConceptScore W4310104977C3018657049 @default.
• W4310104977 hasConceptScore W4310104977C54355233 @default.
• W4310104977 hasConceptScore W4310104977C71924100 @default.
• W4310104977 hasConceptScore W4310104977C86803240 @default.
• W4310104977 hasIssue "Supplement 1" @default.
• W4310104977 hasLocation W43101049771 @default.
• W4310104977 hasOpenAccess W4310104977 @default.
• W4310104977 hasPrimaryLocation W43101049771 @default.
• W4310104977 hasRelatedWork W1493637296 @default.
• W4310104977 hasRelatedWork W2014302553 @default.
• W4310104977 hasRelatedWork W2043879964 @default.
• W4310104977 hasRelatedWork W2151445290 @default.
• W4310104977 hasRelatedWork W2161996216 @default.
• W4310104977 hasRelatedWork W2614629048 @default.
• W4310104977 hasRelatedWork W2737199857 @default.
• W4310104977 hasRelatedWork W3009733369 @default.
• W4310104977 hasRelatedWork W4220986427 @default.
• W4310104977 hasRelatedWork W4311114936 @default.
• W4310104977 hasVolume "140" @default.
• W4310104977 isParatext "false" @default.
• W4310104977 isRetracted "false" @default.
• W4310104977 workType "article" @default.